Adamax vs NSI-189
A side-by-side research comparison of Adamax and NSI-189 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Adamax | NSI-189 |
|---|---|---|
| Full name | Adamax (Semax Analog Nootropic Peptide) | NSI-189 Phosphate (Neurogenic Compound) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research peptide | Investigational |
| Mechanism | As an ACTH/melanocortin-derived peptide analog, it is proposed to elevate BDNF and other neurotrophic factors, modulate the dopaminergic and serotonergic systems, and provide neuroprotection, similar to but reportedly more potent and longer-acting than Semax. | Stimulates hippocampal neural stem cell proliferation and differentiation via Akt/CREB/BDNF signaling. Increases hippocampal volume visible on MRI. |
| Molecular weight | ~ (short peptide) | 366.4 Da |
| Half-life | Short (extended vs Semax) | 18-22 hours |
| Bioavailability | Intranasal or subcutaneous | High (oral) |
| Typical dose | Low microgram-to-milligram range (research) | 40-80 mg |
| Frequency | 1-2x daily | Once daily |
| Route | Intranasal or subcutaneous | Oral |
Adamax reported benefits
- Cognitive enhancement and focus
- Memory support
- Neuroprotection
- BDNF elevation (proposed)
- Mood support
NSI-189 reported benefits
- Hippocampal neurogenesis
- Measurable brain volume increase
- Cognitive enhancement
- Antidepressant effects
- Long-term neural benefit
Related comparisons
Research and educational reference only. Not medical advice.